Provided by Tiger Trade Technology Pte. Ltd.

Sight Sciences, Inc.

8.47
-0.0900-1.05%
Post-market: 8.470.00000.00%16:15 EDT
Volume:233.48K
Turnover:1.99M
Market Cap:466.60M
PE:-15.22
High:8.64
Open:8.40
Low:8.35
Close:8.56
52wk High:9.71
52wk Low:3.19
Shares:55.09M
Float Shares:37.29M
Volume Ratio:0.53
T/O Rate:0.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5564
EPS(LYR):-0.7369
ROE:-48.42%
ROA:-10.84%
PB:8.82
PE(LYR):-11.49

Loading ...

Sight Sciences Price Target Raised to $10.00/Share from $8.00 by Citigroup

Dow Jones
·
Yesterday

Sight Sciences Hosts ASOA Live Interventional Glaucoma Dinner Series at AAO Annual Meeting

Reuters
·
Oct 01

Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting

GlobeNewswire
·
Oct 01

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15

GlobeNewswire
·
Sep 02

Sight Sciences TearCare Wins FDA Label Expansion to Improve Meibomian Gland Function in Dry Eye Patients

Reuters
·
Aug 19

Sight Sciences Names Rashid Kashif as Chief Legal Officer in Initial Beneficial Ownership Filing

Reuters
·
Aug 19

Sight Sciences Earnings Call Shows Growth And Discipline

TIPRANKS
·
Aug 18

Sight Sciences price target raised to $8 from $6 at Citi

TIPRANKS
·
Aug 17

Citi Remains a Hold on Sight Sciences (SGHT)

TIPRANKS
·
Aug 14

Sight Sciences Names Kashif Rashid Chief Legal Officer, Replacing Jeremy Hayden

Reuters
·
Aug 10

Sight Sciences is Maintained at Buy by UBS

Dow Jones
·
Aug 07

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Sight Sciences (SGHT)

TIPRANKS
·
Aug 07

UBS Adjusts Price Target on Sight Sciences to $8 From $7, Maintains Buy Rating

MT Newswires Live
·
Aug 06

Tarsus Pharmaceuticals Q2 Sales Beat Estimates, Lifts 2026 Xdemvy Sales Outlook

Reuters
·
Aug 06

Germany's Carl Zeiss Meditec 9-Month Revenue Falls 2.9%

Reuters
·
Aug 06

Sight Sciences, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Sight Sciences Publishes Investor Presentation on Interventional Glaucoma, Dry Eye Platforms

Reuters
·
Aug 06

Sight Sciences Q2 2026 Earnings: Dry Eye Growth Supports Higher Revenue Guidance

TradingKey
·
Aug 06

Sight Sciences Q2 Revenue Rises 20%, Beats Estimates

Reuters
·
Aug 06

Sight Sciences Q2 EPS $(0.08) Beats $(0.15) Estimate, Sales $23.388M Beat $21.682M Estimate

Benzinga Earnings
·
Aug 06